Takeda Pharmaceutical Company Limited (TAK)

NYSE: TAK · Real-Time Price · USD

17.85

+0.03 (0.17%)

At close: Apr 14, 2026, 4:00 PM EDT

17.85

0.00 (0.00%)

After-hours: Apr 14, 2026, 7:00 PM EDT

Takeda Pharmaceutical Income Statement

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Revenue	4,464,580	4,581,550	4,263,760	4,027,480	3,569,010	3,197,810
Revenue Growth (YoY)	-1.13%	7.45%	5.87%	12.85%	11.61%	-2.84%
Cost of Revenue	1,547,940	1,580,220	1,426,680	1,244,070	1,106,850	994,308
Gross Profit	2,916,650	3,001,330	2,837,080	2,783,410	2,462,160	2,203,500
Selling, General & Admin	1,088,140	1,104,770	1,053,820	997,309	886,361	875,663
Depreciation & Amortization Expenses	609,493	643,233	652,117	542,443	472,915	421,864
Research & Development	696,573	730,227	729,924	633,325	526,087	455,833
Other Operating Expenses	175,082	180,521	187,148	119,823	115,952	-59,125
Total Operating Expenses	2,569,288	2,658,751	2,623,009	2,292,900	2,001,315	1,694,235
Operating Income	347,461	342,586	214,075	490,505	460,844	509,269
Interest Income	222,539	42,563	58,566	54,283	8,333	105,597
Interest Expense	-364,696	-210,065	-219,850	-169,698	-166,607	-248,631
Total Non-Operating Income (Expense)	-142,157	-167,502	-161,284	-115,415	-158,274	-143,034
Pretax Income	205,404	175,084	52,791	375,090	302,571	366,235
Provision for Income Taxes	92,154	66,941	-91,406	58,052	72,405	-9,936
Net Income	112,841	107,928	144,067	317,017	230,059	376,005
Minority Interest in Earnings	-92	215	130	21	107	166
Net Income to Common	112,841	107,928	144,067	317,017	230,059	376,005
Net Income Growth	8.24%	-25.09%	-54.55%	37.80%	-38.81%	749.90%
Shares Outstanding (Basic)	3,152	3,158	3,129	3,104	3,127	3,124
Shares Outstanding (Diluted)	3,176	3,211	3,161	3,140	3,154	3,147
Shares Change (YoY)	0.78%	1.58%	0.67%	-0.46%	0.23%	0.47%
EPS (Basic)	35.97	34.18	46.05	102.14	73.57	120.36
EPS (Diluted)	35.41	33.62	45.58	100.97	72.94	119.48
EPS Growth	-46.05%	-26.25%	-54.86%	38.44%	-38.96%	745.88%
Shares Outstanding	3,159	3,147	3,138	3,109	3,165	3,127
Free Cash Flow	1,010,630	856,387	540,924	836,499	999,853	899,725
Free Cash Flow Growth	18.01%	58.32%	-35.34%	-16.34%	11.13%	65.80%
Free Cash Flow Per Share	318.17	266.73	171.14	266.42	316.98	285.89
Dividends Per Share	198.000	196.000	188.000	180.000	180.000	180.000
Dividend Growth	1.02%	4.25%	4.44%	-	-	-
Gross Margin	65.33%	65.51%	66.54%	69.11%	68.99%	68.91%
Operating Margin	7.78%	7.48%	5.02%	12.18%	12.91%	15.93%
Profit Margin	2.53%	2.36%	3.38%	7.87%	6.45%	11.76%
FCF Margin	22.64%	18.69%	12.69%	20.77%	28.01%	28.14%
EBITDA	1,094,490	1,103,980	942,077	1,154,910	1,044,000	1,068,940
EBITDA Margin	24.51%	24.10%	22.10%	28.68%	29.25%	33.43%
EBIT	347,461	342,586	214,075	490,505	460,844	509,269
EBIT Margin	7.78%	7.48%	5.02%	12.18%	12.91%	15.93%
Effective Tax Rate	44.86%	38.23%	-173.15%	15.48%	23.93%	-2.71%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q